Business
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and
About this update from Lantern Pharma Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY.\n\n\nWebcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html\n\n\nConference Registration Link: https://www.wsw.com/webcast/tep25/ltrn/1700352\n\n\nLantern Pharma management will be available for one-on-one meetings held throughout the conference.\n\nAbout Lantern Pharma:\n\nLantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.5 million per program.\n\nOur lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.\n\nPlease find more information at:\n\n\nWebsite: www.lanternpharma.com\n\n\nLinkedIn: https://www.linkedin.com/company/lanternpharma/\n\n\nX: @lanternpharma\n\n\nForward-looking Statements:\n\n...